We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Spike in FDA Warning Letters to Slow Indian Generics in U.S.
Spike in FDA Warning Letters to Slow Indian Generics in U.S.
The sharp increase in FDA warning letters to Indian facilities last year will lead to a significant delay in U.S. generic launches by Indian drugmakers, according to CRISIL, an Indian research firm.